How Long Does Ground-Glass Opacity Last After COVID?

Ground-glass opacities after COVID-19 follow a general pattern of gradual improvement, but for a meaningful minority of patients the haze on a CT scan sticks around far longer than most people expect. At three months, roughly three-quarters of hospitalized patients still show some GGO. By six months the number drops to somewhere around 40 to 50 percent. At the one-year mark, a meta-analysis puts persistent GGO at about one in five patients. And even at two years, about a third of patients followed in prospective studies still have mild residual changes visible on imaging. The trajectory depends heavily on how sick you were in the first place and a handful of other risk factors worth understanding.

What the First Three Months Typically Look Like

If you had a CT scan during your acute COVID infection and saw widespread white haze across both lungs, the good news is that most of that resolves within the first few months. The bad news is that “most” does not mean “all,” and full radiological clearance in the first three months is actually uncommon among patients who were sick enough to be hospitalized. In one French study that scanned patients about three months after COVID pneumonia, GGO was still present in about 75% of them, with roughly 30% also showing a pattern called reticulation and 13% showing early signs of fibrosis-like changes.¹ A separate follow-up study of severe cases found an even higher rate: only about 15% of patients had complete radiological resolution at three months, while 85% still had persistent GGO.²

Those numbers can sound alarming if you are staring at a follow-up CT report. But context matters here. The patients in these studies were predominantly hospitalized, many with moderate-to-severe pneumonia. If your COVID case was mild and you never had significant lung involvement, your odds of persistent GGO at three months are considerably lower. The studies also show that even among those who still have opacities, the extent of lung involvement typically shrinks over time. A scan that showed dense bilateral GGO at week two might show only scattered, faint patches at week twelve.

One detail that stood out in the severe-case study: the persistence of GGO at three months was strongly linked to how long a patient was hospitalized and whether they needed mechanical ventilation or high-flow oxygen during the acute phase.² In other words, the severity of the initial hit to your lungs is one of the strongest predictors of how quickly the haze clears.

The Six-Month Picture

By six months, the numbers improve substantially but remain higher than many patients and even some clinicians initially anticipated. Multiple studies have tracked patients to this timepoint and found GGO in roughly 40 to 50 percent of those with long COVID symptoms.³ A six-month chest CT follow-up study published in Radiology found that about 42% of patients still had GGO, while 72% showed fibrosis-like changes of some kind.⁴

That said, the picture can vary a lot depending on the population studied. A large Chinese cohort that looked at patients about six months out found residual lung abnormalities in about 36% and fibrotic-like changes in around 14%.⁵ The spread between these studies likely reflects differences in how severe the initial illness was across each cohort, as well as differences in how strictly “abnormal” was defined on imaging. The general trend, though, is clear: the lungs keep healing through this period, but about a third to half of hospitalized patients still carry some visible footprint of the infection at the half-year mark.

One Year and Beyond

A systematic review and meta-analysis that pooled data from multiple studies found that at one year after COVID-19, about a third of patients still had some kind of residual CT abnormality. GGO specifically was present in roughly 21% of patients, and fibrosis-like changes in about 21% as well.⁶ That same analysis showed a clear trajectory of improvement: mid-term follow-up (roughly three to six months) showed abnormalities in about 53% of patients, dropping to 33% at one year. Recovery was continuing, just slowly.

The severity split is striking. Among patients who had severe or critical illness, about 38% still had CT abnormalities at one year, compared to about 21% of those who had mild or moderate disease.⁶ This is one of the most consistent findings across the literature: how sick you were during the acute infection remains the single biggest driver of long-term lung changes.

At the two-year mark, studies suggest that a plateau begins to form. A prospective cohort that followed patients to 24 months found that about 32% still had residual changes, including mild GGO, reticulation, and traction bronchiectasis, mainly in the lower lobes.⁷ Another two-year follow-up found that among patients with reduced lung capacity at 24 months, about 75% had fibrotic-type GGO visible on their scans.⁸ By this point, the remaining abnormalities tend to be more stable, and the question shifts from “when will this resolve” to “is this permanent scarring.”

Who Is More Likely to Have Lingering Opacities

Several risk factors keep surfacing across studies, and they paint a consistent picture. A one-year follow-up study found that patients with residual abnormalities were older, more likely to be current smokers, more likely to have high blood pressure, and more likely to have had secondary bacterial infections and lower oxygen levels during the acute phase. When the researchers ran a statistical model accounting for all these factors, age stood out as an independent predictor: each additional year of age raised the odds of still having abnormalities on the scan.⁹

Another study reinforced the age finding: patients who developed fibrotic-like changes were on average about nine years older than those who did not.¹⁰ A prospective UK cohort similarly found that those with persisting GGO and reticular changes were older, had worse baseline fitness, were more likely to have high cholesterol, and were more often former or current smokers. Interestingly, having a pre-existing chronic lung condition like asthma or COPD did not predict persistent changes in that study.¹¹

In practical terms, the profile of someone most likely to have GGO lingering at six months or beyond tends to be: older, had a severe acute illness requiring oxygen or ventilation, spent a longer time in the hospital, and had cardiovascular risk factors like smoking or hypertension. Younger adults who had moderate pneumonia but recovered without intensive care tend to clear their opacities more quickly and more completely.

Does Persistent GGO Mean Your Lungs Are Not Working Properly

This is one of the most important questions for patients who get follow-up imaging and see “residual GGO” on their report. The short answer is that GGO and lung function do correlate, but the relationship is imperfect. Some people have visible haze on a CT scan and breathe just fine. Others have relatively mild-looking imaging but measurable limitations in gas exchange.

The three-month study mentioned earlier found statistically significant links between GGO and reduced lung function measures, including how much air the lungs could hold and how efficiently they transferred oxygen into the bloodstream.¹ At two years, among patients who had reduced lung capacity, most also had fibrotic GGO on their scans, and those with reduced gas transfer capacity frequently had fibrotic-type GGO and noticeable breathlessness during daily activities.⁸

The distinction between “inflammatory” GGO and “fibrotic” GGO matters here. Early on, the haze on a CT scan often represents ongoing inflammation or fluid in the tiny air sacs. This kind of GGO tends to resolve as the inflammation settles. Later, GGO that persists alongside structural changes like traction of the airways or thickened lines between lung segments is more likely to represent early scarring. The fibrotic type is less likely to reverse and more likely to correspond with lasting breathlessness.

Organizing Pneumonia as a Treatable Cause

Not all persistent GGO after COVID represents irreversible scarring. One pattern that doctors look for is organizing pneumonia, a condition where inflammatory tissue fills the small airways and air sacs. This can develop as a secondary process after the initial viral pneumonia clears. It looks like GGO or consolidation on a CT scan and can mimic worsening fibrosis, but it often responds well to corticosteroid treatment.

Case reports have documented biopsy-confirmed organizing pneumonia developing after COVID, with patients improving significantly after starting high-dose corticosteroids.¹²¹³ This is worth flagging because a patient whose GGO is not clearing, or is actually getting worse weeks to months after infection, may have a condition that responds dramatically to the right medication. If you are in that situation, it is worth discussing with your doctor whether the pattern on imaging might suggest organizing pneumonia rather than irreversible fibrosis.

Treatment Options for Persistent Lung Changes

This is an area where the evidence is still maturing and where the answers are more frustrating than patients would like.

Corticosteroids are the most studied intervention. During the acute phase, steroids like methylprednisolone have been shown to reduce GGO on imaging.¹⁴ But for the later, chronic phase of persistent lung disease? A randomized trial testing prednisolone for post-COVID interstitial lung disease found that the steroid group did not improve any faster than the placebo group. Both groups got better over six months, which is actually the most important takeaway: the natural trajectory of this condition is progressive improvement over time, which makes it hard to prove that any treatment is adding benefit on top of the body’s own healing.¹⁵

Antifibrotic medications, which were originally developed for a different lung-scarring condition called idiopathic pulmonary fibrosis, have generated interest as a potential treatment. Drugs like pirfenidone have been tried off-label. A systematic review and meta-analysis concluded that antifibrotics may help reduce fibrotic lesions and improve lung function, but acknowledged that the evidence is largely theoretical and empirical rather than backed by robust clinical trials.¹⁶ A retrospective study that specifically looked at pirfenidone use in post-COVID patients found that CT scores improved over six months regardless of treatment, and no significant link was detected between the antifibrotic and the degree of improvement.¹⁷

Pulmonary rehabilitation, which combines exercise training, breathing exercises, and education, has a more encouraging evidence base. It does not erase GGO from a CT scan, but it can improve exercise tolerance, breathlessness, and quality of life in people living with post-COVID lung changes.¹⁸ For many patients, the functional gains from rehab matter more than whether a radiologist can still see faint haze on a scan.

Biomarkers That May Predict Who Will Heal and Who Will Not

One of the frustrations of follow-up CT scans is that they show you what has already happened, not what is going to happen. Researchers have been looking for blood markers that might predict, early on, which patients will develop lasting lung changes. A prospective cohort study found that elevated baseline levels of two specific proteins, MMP-7 and KL-6, were associated with having persistent interstitial abnormalities at 12 months.⁷ Both of these are proteins involved in lung repair and fibrosis pathways, and they are already used in clinical settings to monitor other scarring lung diseases. Whether they will eventually become routine tests for post-COVID patients remains to be seen, but they represent a promising avenue for identifying high-risk patients earlier.

How COVID Compares to Other Viral Lung Infections

COVID-19 was not the first coronavirus to leave persistent lung changes. SARS (the 2003 outbreak) and MERS also caused lingering radiological abnormalities. In SARS, a pattern of reticulation became evident after the second week and persisted in about half of patients after four weeks. MERS showed organizing pneumonia patterns during the second and third weeks of infection.¹⁹ Long-term follow-up studies of SARS survivors documented lung function deficits and imaging abnormalities persisting for years in some cases, which provides a precedent for what we are seeing with COVID-19.

GGO is also a common feature of other viral pneumonias, including influenza, though the patterns differ. A study comparing CT findings between COVID-19 and influenza pneumonia found that while both conditions produce GGO, it was more common in COVID-19 (about 88% of cases versus 68% in influenza). COVID-19 also showed more distinctive features like subpleural sparing, where the outermost edges of the lung tissue are relatively clear, while influenza was more likely to cause pleural effusion, or fluid buildup around the lungs.²⁰

When GGO on a Follow-Up Scan Might Not Be From COVID

This is a point that occasionally gets lost in post-COVID follow-up care. Ground-glass opacity is a description of what the lung looks like on imaging, not a diagnosis. It can be caused by dozens of different conditions. If you had COVID and then get a CT scan months later showing GGO, the natural assumption is that the haze is leftover from the infection. That is often correct, but not always.

A radiomics study that analyzed GGO from various causes found that non-COVID conditions producing similar imaging patterns included cytomegalovirus pneumonia, pulmonary edema, acute respiratory distress syndrome from other causes, Pneumocystis pneumonia, Legionella infection, alveolar hemorrhage, and hypersensitivity pneumonia, among others.²¹ In clinical practice, this means that a new or worsening area of GGO on a follow-up scan should not be automatically attributed to slow COVID recovery. If the pattern changes, if new areas appear, or if symptoms take a sudden turn for the worse, your doctor may need to consider other possibilities. Drug reactions, new infections, autoimmune flares, and even early malignancies can all produce GGO. The post-COVID label should not make anyone lazy about differential diagnosis.

Children and Younger Patients

Most of the long-term follow-up data comes from adult populations, and specifically from adults who were hospitalized. Children and adolescents with COVID-19 tend to have less severe lung involvement in the first place, which generally translates to faster radiological recovery. In pediatric imaging studies, the most common CT findings were consolidation and GGO, but these were seen in a minority of cases and tended to be milder in extent.²² The sparse long-term pediatric data available so far suggests that children clear lung abnormalities more quickly and are far less likely to develop the kind of fibrotic changes seen in adults, though formal multi-year follow-up studies in this group are still limited.

Vaccination and Viral Variant Differences

A reasonable question many patients ask is whether vaccination before infection, or being infected by a particular variant, changes the likelihood or duration of lung damage. The evidence here is mixed. One study comparing CT findings in vaccinated and non-vaccinated patients found that in an initial analysis, vaccination status was linked to which variant a patient was infected with (vaccinated patients were more likely to have the Omicron variant, unvaccinated patients more likely to have Delta). However, after accounting for the variant and stage of infection in a more rigorous statistical model, the associations between vaccination and imaging findings became unclear.²³

What is generally accepted, even without a single definitive trial, is that vaccination reduces the likelihood of severe pneumonia, and severe pneumonia is the strongest predictor of persistent GGO. By that logic, vaccination almost certainly reduces the risk of long-term lung changes indirectly, even if the direct imaging comparisons are muddied by variant differences and confounding variables. Later variants like Omicron also tend to cause less lower-respiratory-tract involvement than earlier strains, which further complicates any clean comparison between eras of the pandemic.

1
PubMed Central. Residual ground glass opacities three months after Covid-19 pneumonia correlate to alteration of respiratory function: The post Covid M3 study
2
PubMed Central. Multidimensional 3-Month Follow-Up of Severe COVID-19: Airways beyond the Parenchyma in Symptomatic Patients
3
PubMed Central. Ground glass opacities of the lung before, during and post COVID-19 pandemic
4
PubMed Central. Post-Acute Sequelae of COVID-19 Pneumonia: Six-month Chest CT Follow-up
5
PubMed Central. CT-based Assessment at 6-Month Follow-up of COVID-19 Pneumonia patients in China
6
PubMed Central. One-year follow-up CT findings in COVID-19 patients: A systematic review and meta-analysis
7
PubMed Central. A prospective cohort study for characterization and predictive factors of long-term POST-COVID interstitial changes
8
PubMed. COVID-19 after 2 Years from Hospital Discharge: A Pulmonary Function and Chest Computed Tomography Follow-Up Study
9
PubMed Central. One-year follow-up of chest CT findings in patients after SARS-CoV-2 infection
10
Emerg Med Inves. Persistent Pulmonary Abnormalities Following Hospitalization for Moderate or Severe COVID-19: Unmasking the Risk Factors
11
BMJ Open Respiratory Research. Radiological abnormalities persist following COVID-19 and correlate with impaired health-related quality of life: a prospective cohort study of hospitalised patients
12
PubMed Central. Secondary organizing pneumonia after coronavirus disease 2019: Two cases
13
PubMed Central. Late Onset of Organizing Pneumonia Following SARS-CoV-2 Infection: A Case Report of Successful Management and Review Literature
14
PubMed Central. Effectiveness of corticosteroids on chest high-resolution computed tomography features of COVID-19 pneumonia
15
The Brazilian Journal of Infectious Diseases. Corticosteroid treatment for post-COVID-19 persistent interstitial lung disease: a randomized clinical trial
16
PubMed. Impact of anti-fibrotic medications on post-COVID-19 pulmonary fibrosis: A systematic review and meta-analysis
17
Monaldi Archives for Chest Disease. Impact of antifibrotics on post-COVID-19 lung sequelae
18
PubMed Central. Post-COVID-19 Pulmonary Fibrosis: Facts-Challenges and Futures: A Narrative Review
19
PubMed Central. Imaging findings in coronavirus infections: SARS-CoV, MERS-CoV, and SARS-CoV-2
20
PubMed Central. Differentiation of Chest CT Findings Between Influenza Pneumonia and COVID-19: Interobserver Agreement Between Radiologists
21
Scientific Reports. Radiomics-based machine learning differentiates “ground-glass” opacities due to COVID-19 from acute non-COVID-19 lung disease
22
PubMed Central. Clinical and radiological characteristics of pediatric patients with COVID-19: focus on imaging findings
23
Scientific Reports. Pulmonary computed tomographic manifestations of COVID-19 in vaccinated and non-vaccinated patients